MINI FUTURE SHORT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 03:43:57 2024-05-17 pm EDT | ||
| 22.67 EUR | -2.03% |
|
| Current month | -18.51% | ||
| 1 month | -18.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 22.67 | -2.03% |
| 24-05-16 | 23.14 | -1.20% |
| 24-05-15 | 23.42 | -3.58% |
| 24-05-14 | 24.29 | +0.21% |
| 24-05-13 | 24.24 | -2.88% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 03:43 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7M2D |
| ISIN | DE000ME7M2D0 |
| Date issued | 2024-01-25 |
| Strike | 691.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 22.94 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 28.08 € |
|---|---|
| Lowest since issue | 22.67 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
